Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Low Grade Serous Ovarian Cancer × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 69 Breast Neoplasms 45 Prostatic Neoplasms 28 Neoplasms 25 Multiple Myeloma 24 Parkinson Disease 4, Autosomal Dominant Lewy Body 19 Lung Neoplasms 19 Ovarian Neoplasms 17 Leukemia, Lymphocytic, Chronic, B-Cell 17 Squamous Cell Carcinoma of Head and Neck 16 Myasthenia Gravis 16 Leukemia, Myeloid, Acute 15 Neoplasm Metastasis 14 Colorectal Neoplasms 14 Lymphoma, Follicular 13 Urinary Bladder Neoplasms 12 Stomach Neoplasms 12 Carcinoma, Renal Cell 12 Melanoma 11 Recurrence 10 Carcinoma 10 Small Cell Lung Carcinoma 9 Non-Muscle Invasive Bladder Neoplasms 9 Fallopian Tube Neoplasms 8 Endometrial Neoplasms 8 Lymphoma, Non-Hodgkin 7 Lymphoma, Large B-Cell, Diffuse 7 Lymphoma 7 Glioblastoma 7 Colonic Neoplasms 7

Interventions

liposomal doxorubicin 1 defactinib 1 Paclitaxel 1 Letrozole 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06072781 2026-03-17

RAMP 301

Verastem, Inc.

Phase 3 Recruiting

Low Grade Serous Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡